Quick Answer
ZEVRA THERAPEUTICS, INC. reported Long-Term Debt of $61.93 million for fiscal year 2025.
ZEVRA THERAPEUTICS, INC. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $61.93M | +4.1% |
| 2024 | $59.50M | +1074.6% |
| 2023 | $5.07M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $61.31M | +4.1% | +1.0% |
| June 30, 2025 | $60.69M | +4.1% | +1.0% |
| March 31, 2025 | $60.09M | — | +1.0% |
| December 31, 2024 | $59.50M | +1074.6% | +1.0% |
| September 30, 2024 | $58.90M | — | +1.0% |
| June 30, 2024 | $58.33M | — | +1051.4% |
| December 31, 2023 | $5.07M | — | +548.7% |
| September 30, 2020 | $781.0K | — | +0.0% |
- ZEVRA THERAPEUTICS, INC. showed an increase of +4.1% in Long-Term Debt compared to the prior fiscal year.
- Over the 2023–2025 period, ZEVRA THERAPEUTICS, INC.’s long-term debt has grown by 1122.4% (from $5.07 million to $61.93 million).
- The most recent figure is from ZEVRA THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: